The latest from BioStock
Read BioStock's newsletter for v.20 here.
Watch the latest episode of The IPO round in the banner below
Morning news
initiates structured process for out-licensing ICOpre in collaboration with global investment bank. Read more.
AlzeCures alzheimer's project NeuroRestore ACD856 A European patent is also granted. Read more.
Mentice receives an order for simulation solutions worth $2,4 million from a global medtech company. Read more.
EQL Pharma out-licensing Memprex to Majorelle Laboratories for the French market. Read more.
Medim begins calculation period for exercise price in TO6. Read more.
BioArctics application for marketing authorization for lecanemab is filed in the United Kingdom. Read more.
Marking publishes information to shareholders regarding financing. Read more.
Inhalation Sciences receives a new order worth 53 euros from a returning customer. Read more.
SelectImmune presents Hamlet BioPharma for investors. Read more.
It's almost time for BioStock Life Science Spring Summit!
Interim reports:
Alvotech Cereno Scientific Dicot Kancera PharmaLundensis
Invitations:
Insider trading:
Communiqués:
News since Friday lunch
Genmabs EPKINLY has been approved by the FDA as the first and only bispecific antibody to treat adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Read more.
BBS-Bioactive Bone Substitutes announced that the subscription period for the second series of warrants will begin on May 22, 2023. Read more.
DBP International signed a distribution agreement with a Turkish company for Temodex. Read more.
QuiaPEG received Notice of Allowance in the US regarding the technology platform Uni-Qleaver. Read more.
Vicore announced new 36-week results from the AIR study showing continued disease stabilization and increased lung function in IPF patients. Read more.
Kancera SEK 5,9 million was added through the exercise of warrants. Read more.
PExA announced that they will be exhibiting at a major lung congress in the United States. Read more.
BergenBio updated key information regarding the rights issue. Read more.
Bactiguard Holding has made changes in management. Read more.
This morning's price development
Winner: Calmark 29,5%, Redwood Pharma 16,1%, Mentice 13,8%, Inhalation Sciences 13%, Intervacc 11,5%
Förlorare: Miris Holding -25,9%, OncoZenge -12,3%, Spermosens -11,8%, Isofol Medical -11,3%, ProstaLund -10,1%
Index: OMXS30 2, -282%, Healthcare -0,24%